Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25979547 | 0.97 | PRKDC (0.36) | PRKDCALOX5APPESR2TNKS | |
| SCHEMBL25979130 | 0.96 | PRKDC (0.34) | PRKDCALOX5LIMK1PIM1PIM3 | |
| SCHEMBL25978807 | 0.93 | PRKDC (0.34) | PRKDCALOX5 | |
| SCHEMBL25980097 | 0.91 | PRKDC (0.34) | PRKDCALOX5ESR2MAPT | |
| SCHEMBL25980166 | 0.91 | PRKDC (0.36) | PRKDCALOX5ESR2 | |
| SCHEMBL26778715 | 0.90 | PRKDC (0.35) | PRKDCALOX5ATML3MBTL1MAPT | |
| SCHEMBL21866644 | 0.90 | PRKDC (0.33) | PRKDCALOX5 | |
| SCHEMBL25978261 | 0.89 | PRKDC (0.37) | PRKDCALOX5LIMK1 | |
| SCHEMBL25980465 | 0.88 | LIMK1 (0.38) | ALOX5LIMK1ABCG2ATMMAPT | |
| SCHEMBL25979716 | 0.88 | APP (0.32) | APPABCG2MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365538-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365538-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-4227301-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT Materials Co., Ltd. (KR) | 2023-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365538-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | PRKDC 4556/4885ALOX5 660/4885APP 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.